DMAA

#3442
Drugs Made In America Acquisition Corp. - Ordinary Shares
10.7 5 USD
0.00%
Market Price
Settore: Finanziario
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
10.75
10.75
Intervallo Annuale
10.40
10.76
Variazione giornaliera
-0.09%
Variazione Mensile
+0.47%
Variazione di 6 mesi
+2.73%
Variazione Annuale
+2.97%
Chiusura Precedente
10.7 6
Open
10.7 5
Minimo
10.7 5
Massimo
10.7 5
Volume
1
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Drugs Made In America Acquisition Corp. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Drugs Made In America Acquisition Corp. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Drugs Made In America Acquisition Corp. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Drugs Made In America Acquisition Corp. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Drugs Made In America Acquisition Corp. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Drugs Made In America Acquisition Corp. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Drugs Made In America Acquisition Corp. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Drugs Made In America Acquisition Corp. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Drugs Made In America Acquisition Corp. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Drugs Made In America Acquisition Corp. current report, Q1 FY2026
8-K

Drugs Made In America Acquisition Corp. current report, Q1 FY2025

Full document

Business Context and Reporting Period

Company: Drugs Made In America Acquisition Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: February 20, 2025
Reporting Period: Specific event date of February 20, 2025, with effective action on or about February 25, 2025.

The Company is a Cayman Islands corporation and an emerging growth company. It is currently in the pre-business combination phase, trading Units on The Nasdaq Stock Market LLC.

Key Financial Metrics

This filing is a Current Report (Form 8-K) regarding a corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.

Material Changes

The material change reported is the upcoming separation of the Company's Units into their underlying components:

  • Event: Holders of Units may elect to separately trade the ordinary shares and rights included in the Units on or about February 25, 2025.
  • Unit Composition: Each Unit consists of one ordinary share and one right.
  • Trading Symbols:
    • Units (if not separated): DMAAU
    • Separated Ordinary Shares: DMAA
    • Separated Rights: DMAAR
  • Procedure: Unit holders must instruct their brokers to contact VStock Transfer LLC, the Company's transfer agent, to effect the separation.

Guidance, Outlook, and Risks

Management Commentary: The filing announces the logistical details of the separate trading of securities. No forward-looking financial guidance or strategic outlook is provided in this document.

Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the operational requirement for shareholders to coordinate with brokers and the transfer agent to separate their holdings.

Investor Verification Checklist

  • Confirm the specific deadline and process with your broker to separate Units into shares (DMAA) and rights (DMAAR) if desired.
  • Verify the trading status of the three symbols (DMAAU, DMAA, DMAAR) on Nasdaq starting February 25, 2025.
  • Review the attached Press Release (Exhibit 99.1) for any additional details on the separation mechanics not included in the 8-K summary.
  • Check for subsequent filings regarding the Company's status as an emerging growth company and any potential business combination targets.